IGKV1-6

Across TCGA pan-cancer cohorts, IGKV1-6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGKV1-6 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IGKV1-6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV1-6 expression acts as an unfavorable survival marker.

LIHC, LUSC, and PRAD are the cancer types where IGKV1-6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.033	0.784	<.001	24	view →
LUSC	OS	Median	All	0.081	0.818	.008	20	view →
PRAD	DFS	Median	All	0.096	0.778	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.281	0.707	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IGKV1-6–LIHC (OS)

Open the LIHC breakdown →